-
公开(公告)号：US20220313724A1
公开(公告)日：2022-10-06
申请号：US17744634
申请日：2022-05-14
IPC分类号： A61K31/713 , A61K47/59 , A61K31/7084 , A61K39/395 , A61P35/00 , A61K9/00
摘要： The present invention relates to cancer treatment strategies comprising specific combinations of compounds or compositions that are administered intratumorally and can exert both local and distant anti-tumor effects. Preferred compounds and compositions to be combined for the intratumoral administration include a STING agonist and a TLR3 agonist. The disclosed combinations and related pharmaceutical compositions are additionally useful for inclusion in other cancer therapies such as radiotherapy or antibody-based immunotherapies.
-
公开(公告)号：US20240091350A1
公开(公告)日：2024-03-21
申请号：US18468785
申请日：2023-09-18
IPC分类号： A61K39/39 , A61K9/16 , A61K39/00 , A61K39/395
CPC分类号： A61K39/39 , A61K9/1641 , A61K39/0011 , A61K39/3955 , A61K2039/55561
摘要： The present invention provides pharmaceutical compositions comprising polyinosinic-polycytidylic acid, in particular using particles formed by synthetic polymers, that are adapted for parenteral administration, such as for subcutaneous, intramuscular, or intravenous injection, or infusion. The formulations disclosed herein may be used in a variety of clinical applications, for instance, in methods for administering cell-, peptide-, or nucleic acid-based cancer vaccines or for administering other agents to treat or prevent cancer. The disclosed formulations may also be used in combination with conventional therapies such as radiation therapy, chemotherapy, immunotherapy, cryotherapy, tumor ablation and/or anti-cancer drugs or other standard-of-care medical treatments. Methods for evaluating the presence and effects of polyinosinic-polycytidylic acid in biological samples from subjects treated with pharmaceutical compositions comprising particles formed by synthetic polymers and polyinosinic-polycytidylic acid are also provided.
-
公开(公告)号：US20230116048A1
公开(公告)日：2023-04-13
申请号：US17989526
申请日：2022-11-17
IPC分类号： A61K31/713 , A61K9/00 , A61K9/08 , A61K9/19 , C07K16/28 , A61K47/69 , A61K47/26 , A61K47/50 , A61K31/15 , A61K31/74
摘要： The present invention relates to compositions comprising polyinosinic (poly(l)) and polycytidylic acid poly(C) molecules, or a salt and/or solvate thereof, comprising double-stranded polyribonucleotides formed by the respective single-stranded poly(l) and poly(C) molecules and methods of makig same. The present invention further relates to compositions wherein the disclosed respective poly(l) and poly(C) single-stranded molecules are annealed to thereby form double-stranded poly(l:C) molecules.
-
公开(公告)号：US20210060054A1
公开(公告)日：2021-03-04
申请号：US17095059
申请日：2020-11-11
摘要： The present invention relates to compositions comprising particles, each of the respective particles comprising particles formed by polyribonucleotides and polymers. Specifically, the composition comprises a complex of at least one double-stranded polyribonucleotide, such as polyinosinic-polycytidylic acid [poly(I:C)], and at least one linear polyalkyleneimine. The particles are also characterized by their monomodal diameter distribution and z-average diameter within specific ranges. The present invention additionally relates to methods of manufacturing the compositions, and further to related pharmaceutical compositions useful for the treatment of any cell growth disorder characterized by an abnormal growth of human or animal cells.
-
-
-
搜索结果
4 条记录 (耗时 0.012 秒)
